Mabwell Bioscience Announces Formation of Kalexo Bio With Aditum Bio
San Diego – September 17, 2025 – Cooley advised Mabwell Bioscience, an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain, on its exclusive license agreement with Aditum Bio to launch Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target small interfering RNA (siRNA) candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease events.
Under the agreement, Mabwell will grant Kalexo Bio exclusive worldwide rights to develop, manufacture and commercialize 2MW7141. Mabwell is eligible to receive up to $1 billion in upfront and milestone payments, as well as tiered royalties on global sales. This includes $12 million in nonrefundable upfront and near-term cash payments. Mabwell will also receive an equity stake in Kalexo Bio.
The Cooley team was led by life sciences corporate partnering and licensing lawyers Charity Williams and Freddy Yip, as well as corporate lawyers Ken Rollins and Brett Dovman, with valuable support from Jeffrey Tolin and Amanda Pacheco on tax, Andrew Epstein and Zhijing Yu on cyber/data/privacy, Christopher Kimball on CFIUS, David Burns on antitrust, Robert Eisenbach on bankruptcy, Rachel Thorn on dispute resolution, Natasha Leskovsek on US Food and Drug Administration regulatory and Karen Tsai on export control.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.